2017 was a comparatively quiet year for pharma M&A. However, conditions remain ripe for companies to engage in more deal making in 2018. Big Pharma is divesting its non-core assets and doubling down on core business lines. Furthermore, generics portfolios are increasingly being seen as underperforming assets that distract from the bread and butter of…
InFocus
As pharmaceutical and biotech products become more complex and the markets they serve more diverse, the healthcare logistics and distribution industry has had to consistently innovate and evolve to meet the needs of its clients. This report focuses on how this important niche has evolved and what the future holds through interviews with some of…
This report offers companies, investors, policymakers, and stakeholders in-depth analysis of the benefits of blockchain technology in general and BioIPSeeds in particular, as well as expert insights into this game-changing technological breakthrough. The report features in-depth exclusive interviews with the developers of BioIPSeeds, as well as key opinion leaders who weigh in on the…
